Insiders · OPNT

Phil Skolnick

Officer at Opiant Pharmaceuticals, Inc. (OPNT)

Phil Skolnick has filed 10 insider reports with the SEC since January 2021, as officer at Opiant Pharmaceuticals, Inc. (OPNT). Phil Skolnick made no open-market purchases or sales in the last 12 months. The latest filing, on March 3, 2023, reports grant or award and sale back to the company at Opiant Pharmaceuticals, Inc. (OPNT).

Filings
10
Companies
1
Bought on market
None
Sold on market
$105K

Companies where Phil Skolnick is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Opiant Pharmaceuticals, Inc. logo
OPNT
Opiant Pharmaceuticals, Inc.
Officer0$105KMar 3, 2023

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Phil Skolnick with

Questions about Phil Skolnick

What is Phil Skolnick's role at Opiant Pharmaceuticals, Inc.?
Phil Skolnick reports to the SEC as officer at Opiant Pharmaceuticals, Inc. (OPNT), according to the latest filing on March 3, 2023.
Has Phil Skolnick bought or sold stock recently?
The most recent open-market sale was on January 27, 2023: sold 480 shares of Opiant Pharmaceuticals, Inc. (OPNT) for $9,725 at an average of $20.26.
How do I get alerts when Phil Skolnick files?
Follow Phil Skolnick on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Phil Skolnick (SEC CIK 0001358116). Totals count each trade once, skipping amendments whose original is on file, from Jan 27, 2021 on. View on SEC EDGAR · Get this as JSON